Patent · US Active

Compositions and methods for inhibiting expression of CD45 gene

US8288525B2 · kind B2 · utility

0Cited by

2References

14Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Antonin de Fougerolles · Waterloo, BE
Pamela Tan · Kulmbach, DE
Anna Borodovsky · Cambridge, US
Tatiana Novobrantseva · Cambridge, US
Sina Bavari · Dillsburg, US
Kelly Lyn Warfield · Adamstown, US

Key dates

Filing date	Feb 12, 2009
Grant date	Oct 16, 2012
Priority date	—
Expiry date	Feb 12, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/3515
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the CD45 gene.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.